High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Abstract There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12–15 kDa single-domain antibody fragments that can be delivered by inhalation and are amenable to relatively inexpensive large scale production compared to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Thomas J. Esparza, Negin P. Martin, George P. Anderson, Ellen R. Goldman, David L. Brody
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/781613999e5f4819ab8747154b1624dd
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!